
Biocrystal LTD Profile last edited on: 5/20/2019
CAGE: 1SEB8
UEI:
Business Identifier: Nanocrystal technologies Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
575 McCorkle Boulevard
Westerville, OH 43082
Westerville, OH 43082
(614) 818-1170 |
jbergen@biocrystal.com |
www.biocrystal.com |
Location: Single
Congr. District: 04
County: Delaware
Congr. District: 04
County: Delaware
Public Profile
BioCrystal, Ltd. has brought together an interdisciplinary science group into a business structure committed to the development of novel products and procedures for applications in the life sciences and clinical medicine. BioCrystal is focused to product commercialization in three areas: semiconductor-based, nanocrystalline fluorescent markers for cell and intracellular detection and analysis; therapeutic compounds and procedures for the diagnosis and treatment of cancer; and the very innovative OptiCell ®, a product that represents a significant step forward in the evolution of cell and tissue culture technology .Fluorescent Nanocrystals: One of the fundamental tools used in the identification of biological molecules is immunofluorescence, a technique that combines sensitive fluorescent indicators (dyes) with antibodies or proteins that target specific biomolecules in complex mixtures. BioPixels , a new series of fluorescent tags, improve this process. BioPixels have narrow emission spectra and resist photobleaching.They are stable in aqueous solutions, and are produced in a series of colors of the visible spectrum all excitable by the same wavelength of light, and all with narrow, non-overlapping emission spectra. These nanometer-sized crystals are functionalized to allow direct coupling to biological molecules such as proteins, antibodies, lectins and nucleotides. BioCrystal's advanced functionalized coating technology improves fluorescence intensity and biostability. The Treatment of Cancer: Current anticancer therapies basically target the destruction of tumorcells. They marginally address the associated tumor systemic pathology. BioCrystal has discovered the means for controlling tumor biology through a systemic pathology that can be applied in cancer therapy to avoid tumor recurrence and metastasis. The company has demonstrated experimentally that its immune corrective therapy products can significantly reduce the recurrence and spread of cancer. Cell Culture Research Tool - OptiCell ® Since the completion of the Human Genome Project, researchers have focused on the biological behavior and function of a cell population in relation to its genetic profile. Advances in technology have yielded fascinating insights into the ways that cells work. Nonetheless, the fundamental tools for in vitro cell culture have changed little the past 50 years. For the multitude of operations involved in cell culture, a number of different devices and tools are employed, many steps are required, and there is a premium on good laboratory practice to minimize contamination. OptiCell addresses all of these issues. OptiCell improves the efficiency of cell management, reduces the cost of labor in cell and tissue culture practices, creates the means to automate cell culture practices, and will expand the practical use of a disposable cell culture device for diagnostic applications in clinical medicine.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2003 | 2 | Army | $799,032 | |
Project Title: Synthesis and Functionalization of Quantum Dots for Bio Agent Detection |
Key People / Management
Jeffrey R Bergen -- President and CEO
Emilio Barbera-Guillem
Imad Naasani
Emilio Barbera-Guillem
Imad Naasani
Company News
There are no news available.